TY - JOUR T1 - Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy JF - Anticancer Research JO - Anticancer Res SP - 4229 LP - 4232 VL - 37 IS - 8 AU - RYO ARIYASU AU - ATSUSHI HORIIKE AU - TAKAHIRO YOSHIZAWA AU - YOSUKE DOTSU AU - JUNJI KOYAMA AU - MASAFUMI SAIKI AU - TOMOAKI SONODA AU - SHINGO NISHIKAWA AU - SATORU KITAZONO AU - NORIKO YANAGITANI AU - MAKOTO NISHIO Y1 - 2017/08/01 UR - http://ar.iiarjournals.org/content/37/8/4229.abstract N2 - Background/Aim: Adrenal insufficiency is one of the adverse events (AEs) associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can lead to serious conditions. It is necessary to elucidate detailed clinical features of these AEs. Patients and Methods: Patients treated with anti-PD-1 monotherapy or in combination with anti-cytotoxic T cell lymphocyte-4 therapy at our hospital from January 2013 to December 2016 were identified. The patients' clinical characteristics and laboratory and radiologic findings were collected. Results: Adrenal insufficiency occurred in 3% of the patients. All patients were male. At the onset of symptoms, eosinophilia (>500/μl) was observed in four cases. Eosinophilia was observed more than a month before onset of symptoms in three cases. Other pituitary hormones remained relatively stable. Radiological evidence of pituitary inflammation was detected only in one case. Conclusion: Most anti-PD1-related adrenal insufficiency cases involved an isolated ACTH deficiency. Eosinophilia may be an early indicator before the onset of symptoms. ER -